Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical Industries Limited (TEVA)
:TEVA
RESEARCH TOOLSreports
TEVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.51 - $22.80
Previous CloseN/A
Volume1.13M
Average Volume (3M)13.68M
Market Cap
$19.94B
Enterprise Value$40.18B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.53
Next Earnings
May 07, 2025EPS Estimate
0.51Last Dividend Ex-Date
Nov 27, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding1,145,838,700
10 Day Avg. Volume12,549,363
30 Day Avg. Volume13,680,021
Standard Deviation0.12
R-Squared0.10
Alpha0.00699
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.18
Price to Cash Flow (P/CF)8.50
P/FCF Ratio1.60
Enterprise Value/Market Cap2.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.98
Enterprise Value/Ebitda52.19
Forecast
1Y Price Target
$24.50Price Target Upside44.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHigh margin brands like Austedo and Ajovy are expected to add significant sales, offsetting future headwinds.
Product DevelopmentRecent positive Ph2 duvakitug data for UC and Crohn’s seen as a major surprise with potential for further development in fibrotic disorders.
Strategic InitiativesA TAPI deal in the range of $2-3 billion could accelerate the path to long-term leverage target and improve the financial standing of the company.
Bears Say
Competitive DynamicsUncertain competitive dynamics flagged as a net pricing variable for g-Revlimid could affect the generics market.
Market Challenges4Q should be a soft quarter for US generics given TEVA recognizes negligible contribution from its largest generic, Revlimid.
Portfolio RisksTEVA discussed key medium-term portfolio drags, including the Gx Revlimid cliff in 2026 and Austedo IRA by 2027 or 2028, which could create growth headwinds.
---
Ownership Overview
0.41% Insiders
6.70% Mutual Funds
31.04% Other Institutional Investors
58.72% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TEVA FAQ
What was Teva Pharmaceutical Industries Limited’s price range in the past 12 months?
Teva Pharmaceutical Industries Limited lowest stock price was $12.51 and its highest was $22.80 in the past 12 months.
What is Teva Pharmaceutical Industries Limited’s market cap?
Teva Pharmaceutical Industries Limited’s market cap is $19.94B.
When is Teva Pharmaceutical Industries Limited’s upcoming earnings report date?
Teva Pharmaceutical Industries Limited’s upcoming earnings report date is May 07, 2025 which is in 75 days.
How were Teva Pharmaceutical Industries Limited’s earnings last quarter?
Teva Pharmaceutical Industries Limited released its earnings results on Jan 29, 2025. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.707 by $0.003.
Is Teva Pharmaceutical Industries Limited overvalued?
According to Wall Street analysts Teva Pharmaceutical Industries Limited’s price is currently Undervalued.
Does Teva Pharmaceutical Industries Limited pay dividends?
Teva Pharmaceutical Industries Limited pays a Quarterly dividend of $0.072 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical Industries Limited dividends here
What is Teva Pharmaceutical Industries Limited’s EPS estimate?
Teva Pharmaceutical Industries Limited’s EPS estimate is 0.51.
How many shares outstanding does Teva Pharmaceutical Industries Limited have?
Teva Pharmaceutical Industries Limited has 1,145,838,700 shares outstanding.
What happened to Teva Pharmaceutical Industries Limited’s price movement after its last earnings report?
Teva Pharmaceutical Industries Limited reported an EPS of $0.71 in its last earnings report, beating expectations of $0.707. Following the earnings report the stock price went down -13.888%.
Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Limited?
Currently, no hedge funds are holding shares in TEVA
---
Teva Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.50 (44.12% Upside)
$24.50 (44.12% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 193.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.06%
12-Months-Change
Fundamentals
Return on Equity
-25.44%
Trailing 12-Months
Asset Growth
-9.55%
Trailing 12-Months
Company Description
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
---
TEVA Company Deck
---
TEVA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a strong performance in key products and business segments, alongside improvements in credit ratings, but also highlighted challenges such as the impact of macroeconomic factors and the future decline in Revlimid revenue. Despite these challenges, Teva remains optimistic about its growth strategy and product pipeline.Read More>---
TEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
---
TEVA Stock 12 Month Forecast
Average Price Target
$24.50
▲(44.12% Upside)
Technical Analysis
Best Analysts Covering TEVA
1 Year
1 Year Success Rate
12/24 ratings generated profit
1 Year Average Return
+19.88%
reiterated a buy rating 23 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +19.88% per trade.
---